Pasireotide is a somatostatin analog used in the treatment of Cushing’s disease, specifically for those patients whom pituitary surgery is not appropriate. Pasireotide is a synthetic long-acting cyclic hexapeptide with somatostatin-like activity.
- Mechanism
- Curator reviewed
Pasireotide activates a broad spectrum of somatostatin receptors, exhbiting a much higher binding affinity for somatostatin receptors 1, 3, and 5 than octreotide in vitro, as well as a comparable binding affinity for somatostatin receptor 2. The binding and activation of the somatostatin receptors causes inhibition of ACTH secretion and results in reduced cortisol secretion in Cushing's disease patients. Also this agent is more potent than somatostatin in inhibiting the release of human growth hormone (HGH), glucagon, and insulin.
- Primary indication
- For the treatment of Cushing’s disease, specifically for those patients whom pituitary surgery has not been curative or is not an option.Curator reviewed · 3 structured indications
- Formula / weight
- C58H66N10O9 · 1047.2062 g/mol (avg)
- First approval
- Canada, 2020 · United States, 2012 · European Union, 2016
- Code names
- SOM-230
- Brand names
Resolves to
VMZMNAABQBOLAK-DBILLSOUSA-NSMILESNCCCC[C@@H]1NC(=O)[C@@H](CC2=CNC3=C2C=CC=C3)NC(=O)[C@@H](NC(=O)[C@@H]2C[C@H](CN2C(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CC2=CC=C(OCC3=CC=CC=C3)C=C2)NC1=O)OC(=O)NCCN)C1=CC=CC=C1What you can answer from here — as of September 23, 2026
Which drugs share a target with Pasireotide, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account